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Summary
Background: Generally benefits and risks of vaccines can be deter-
mined from studies carried out as part of regulatory compliance, fol-
lowed by surveillance of routine data; however there are some rarer and 
more long term events that require new methods. Big data generated 
by increasingly affordable personalised computing, and from pervasive 
computing devices is rapidly growing and low cost, high volume, cloud 
computing makes the processing of these data inexpensive. 
Objective: To describe how big data and related analytical meth-
ods might be applied to assess the benefits and risks of vaccines. 
Method: We reviewed the literature on the use of big data 
to improve health, applied to generic vaccine use cases, that 
illustrate benefits and risks of vaccination. We defined a use case 
as the interaction between a user and an information system to 
achieve a goal. We used flu vaccination and pre-school childhood 
immunisation as exemplars.
Results: We reviewed three big data use cases relevant to assess-
ing vaccine benefits and risks: (i) Big data processing using crowd-
sourcing, distributed big data processing, and predictive analytics, 
(ii) Data integration from heterogeneous big data sources, e.g. the 
increasing range of devices in the “internet of things”, and (iii) 
Real-time monitoring for the direct monitoring of epidemics as well 
as vaccine effects via social media and other data sources. 
Conclusions: Big data raises new ethical dilemmas, though its 
analysis methods can bring complementary real-time capabilities for 
monitoring epidemics and assessing vaccine benefit-risk balance.
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Big Data for Assessing 
Vaccination Benefits and Risks: 
A Use Case Driven Approach
Introduction
The rapidly reducing cost of data storage and 
the increasing bandwidth of communication 
networks have enabled large volumes of data 
to be mobilised easily. Due to the proliferation 
of social media and cloud computing, the 
collection, storage, and processing of data has 
become much easier allowing large datasets to 
be generated and managed in a cost effective 
manner [1]. It has been reported that the total 
data generated in the last two years exceeds that 
amassed throughout the entire history of the 
digital age [2]. This extended the boundaries of 
data processing and introduced a new perspec-
tive of data analytics embedded in the concept 
of “Big Data”. A quantitative definition of 
“Big Data” is difficult as the “big” volume is 
relative to the time of the definition. Datasets 
considered to be “Big Data” now, may not be 
considered so in the very near future, due to 
technological advancements [3]. This is some-
what in contrast to our conventional approach-
es of study designs where data requirements 
are set to answer a specific research question. 
Processing Big Data
In terms of the nature of data, big data con-
sists of large bodies of unstructured or raw 
data which cannot be processed using con-
ventional, largely relational data processing 
techniques. The complexity of the data is 
often important in characterising datasets 
as big data. Big data is characterised by 
IBM according to four dimensions: volume, 
velocity, variety, and veracity (Box 1) [4]. 
Big data processing methods address issues 
such as data volume and heterogeneity in 
large datasets [5, 6]. 
The Big Data Advantage
The literature suggests that cloud-based pro-
cessing of petabytes of data can be achieved 
at a fraction of the time and cost when adopt-
ing big data processing methods [11]. Whilst 
the wave of big data technologies will not 
resolve the plethora of data issues that exist 
in the health care information ecosystem 
(the system of processing and filtering data 
between data recording and utilisation) [7], 
methods for harnessing big data are con-
sidered to offer the potential to take a big 
step forward in improving the quality and 
efficiency of health care delivery [8].
Method
1   Overview
We have followed an evidence-based 
approach for developing use cases. This 
method has been developed based on a 
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We identified the nature of the dataset 
(if provided), the field of the study within 
health care, the particular methods used 
for manipulating data, and relevance to 
vaccine research. We used “word clouds” 
to indicate the key areas where research 
has been conducted and the methods 
used [9].
3   Generalised Use Case Models
Use cases are commonly applied in the dis-
cipline of software engineering to capture 
scenarios of how various systems are used in 
practice [10]. Our group has the experience 
of developing use cases to support complex 
research questions [11, 12]. Use cases pro-
vide a mechanism of describing the usage 
Fig. 1   Adapted PRISMA flow diagram
Table 1  Evidence table used for building the generalised use cases
bottom-up approach for model creation by 
Regnell et al. [13]. The process started with 
a rapid literature analysis to select use cases 
that captured common usages of big data 
in health care potentially relevant to assess 
the benefits and risks of vaccines. Publica-
tions were identified and key information 
was extracted, focusing specifically on use 
cases of big data. These use cases were then 
evaluated to assess their potentiality to im-
prove research methods of assessing vaccine 
benefits and risks. 
2   Search Strategy
The literature analysis employed is suited 
to the exploratory reviews of emerging 
technologies in a given domain. It relies 
on the fact that there are common usage 
patterns of techniques in the same domain. 
Therefore, a sample of actual uses of big 
data in the domain of interest is sufficient 
for determining the generic usage patterns 
(known here as use cases). 
We searched PUBMED, Medline, Scopus, 
Web of Science, and the Cochrane Database 
for publications related to big data in health 
care. We focused on health care databases, 
using simple search strings. An adapted 
PRISMA flow chart is shown in Fig. 1. We 
included papers which focused primarily on 
conceptual or practical uses of big data in 
health care research. This includes instances 
where big data has been used to highlight 
the volume of data. Electronic searches were 
performed retrospectively to select papers 
published between January 2005 and Decem-
ber 2013. Search was limited to the English 
language. The number of articles from all 
searches totalled 485, with 219 being dupli-
cations Due to big data being a relatively new 
concept, no limits were set/placed regarding 
the type of papers. As such we included any 
review and report on this topic. 
Abstracts were reviewed for applications 
of big data methods in health care. Key infor-
mation from each publication was extracted 
to form a summary (which we refer to as a 
use case instance). After the screening pro-
cess, we grouped the use case instances that 
have common utilisation patterns of big data. 
Groups were then analysed separately to 
build the generalised use cases we describe 
in the next section. 
Generalised use cases
1. Big data processing
2. Data integration of 
heterogeneous big data sources
3. Real-time monitoring
Big data in health care use cases 
(References)
Distributed data processing:
28,29,30,31,32
Predictive analysis:
33,34,35,36,37 
Crowdsourcing:
38,39
45, 46,47,48,49,50,51
61,62,63,64,65,66
Vaccine specific use cases
41,42,43,44
52,53,54,55,56,57,58,59,60
67,68,69,70,71,72,73,74,75,76,77,78,79
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of a system and its associated processes. In 
this approach, specific uses of big data were 
evaluated and generalised to identify big data 
usage patterns (i.e. use cases) commonly 
encountered in the health care domain. 
4   Vaccine Benefits and Risks Use Cases
We are involved in a number of programmes 
that aim to assess the benefits and risks of vac-
cination within the Royal College of General 
Practitioners (RCGP) Research and Surveil-
lance Centre (RSC) [14,15], which has a long 
term interest in the monitoring of influenza 
[16, 17, 18]. We studied the overall benefit-risk 
for two use-case vaccine programmes: influ-
enza and pre-school childhood immunisation, 
with a focus on specific adverse events (AE) 
following immunisation (AEFI) .
This type of research is challenging. 
For example, it may not be clear whether 
a flu-like illness is vaccine preventable. 
Influenza is hard to diagnose precisely and 
to differentiate from other viral upper respi-
ratory and flu-like illnesses without virology, 
which is not carried out in routine practice. 
Flu vaccines are available from a number of 
sources (e.g. vaccination against flu in the 
workplace or school), and it can be hard to 
precisely attribute risk to vaccines; influenza 
vaccine composition varies every year, and 
in addition, different vaccine preparations 
are available each year. Controversy remains 
about possible long term AEFI, in particular 
Guillain Barré Syndrome [19, 20]. To date 
only telephone surveys have been conducted 
to gain more immediate feedback about local 
and short term AEFI. Of particular interest 
is the role of adjuvants [21]. 
Pre-school childhood vaccinations are 
usually combination preparations. Making 
the separation of the responses to vacci-
nation and AEFI is challenging. Passive 
reporting of AEFI has limitations [22]; and 
it appears that both patients and medical 
records under-report febrile seizures that 
are possible AEFIs [23].
The scope of this paper is to explore how 
new types of use cases might be developed 
utilising big data; we will not be addressing 
these approaches to vaccine research. The 
purposes of these use cases are threefold: 
 (1) To demonstrate that by using big 
data techniques, it is possible to process 
massive amounts of data that could not be 
readily processed on a single computer or 
recruited into a traditional study; 
 (2) To integrate data that can emanate 
from a much wider range of observations 
than would generally be used in medical 
research; novel sources of data might 
provide new insights into vaccine benefits 
and risks. Our focus is on the short and 
long term, local and systemic AE fol-
lowing influenza vaccination and febrile 
seizures after pre-school immunisations. 
 (3) To provide real time monitoring, not 
daily or weekly, but “as it happens”. It may 
be much faster to report about effective-
ness and adverse events. This might pro-
vide greater insights into the reactogenicity 
of different preparations and adjuvants. 
Results
The overall result of our analysis was that most 
studies looked at how big data and associated 
methods can be leveraged to enhance standard 
data manipulation methods in different areas 
of studies in health care. A summary of the 
big data methods discussed in the publications 
are highlighted in a word cloud (Fig. 3). In the 
word cloud, “exploration of data” (including 
data mining and pattern analysis) was the 
most emphasised. This is an ubiquitous part 
of any work with big data, and it is essentially 
the process of hypothesis generation or early 
hypothesis testing. We have therefore not 
created a use case around this activity.
Fig. 2  Word cloud of fields in health care represented by literature search results
Fig. 3   Word cloud of big data methods represented by literature search results
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We have generalised the usage of big data 
and associated methods into three main use 
cases (Table 2). 
ods may indeed have limitations when 
handling the scale of datasets associated 
with big data.
• Predictive analytics: This method of 
analysis uses various statistical and data 
mining techniques to analyse historical 
and present data in order to predict future 
outcomes. Predictive analytics is already 
demonstrating its usefulness in applica-
tions that enable a smarter prediction 
of health care outcomes by combining 
clinical, insurance and public datasets. It 
supports “intelligent case management” 
which involves the development of pro-
grams that can have a higher impact on 
patient behaviour [31, 32]. We have found 
evidence for the use of these methods 
in secondary care for purposes ranging 
from reducing readmissions to predicting 
clinical outcomes in patients admitted to 
surgical intensive care units [33, 34, 35].
• Crowdsourcing: This involves recruiting 
large numbers of people who collabo-
ratively collect, filter, and analyse large 
amounts of data for a common purpose. 
Using the internet as the medium of 
participation, thousands of people par-
ticipate in completing a small part of a 
problem (often offered in multiplicity 
for the purpose of validation). Gamified 
approaches (i.e. regular tasks built as 
computer games) have been developed 
for aiding the diagnosis or the labelling of 
biomedical images [36]. In HIV research, 
crowdsourcing has been used to identify 
important genes using 500 billion subsets 
related to HIV biology [37].
Implications for vaccine research: Vaccines 
available on the market are effective against 
only a limited number of circulating strains. 
Genetic variations of viruses (i.e. antigenic 
drift) result in regular reformulations of 
vaccines [38]. This process is costly and 
time consuming and has a direct impact 
specifically during pandemic outbreaks. This 
was evident in the pandemic outbreak of the 
H1N1 virus (Influenza A (H1N1) virus is the 
subtype of influenza A virus that is the most 
common cause of human influenza) where 
vaccines were made available only after the 
first wave of the pandemic [39]. 
Crowdsourcing and cloud computing 
services which provide a dedicated infra-
structure for collecting and processing data 
are now readily available. At present, any 
individual with internet access can launch 
thousands of clusters which could process 
terabytes of data within a few hours. This 
would have taken many months and large 
amounts of money in the prior to utility 
computing era, in which computational capa-
bilities can be leased on a pay-per-use basis. 
Cloud services nowadays are configured with 
the MapReduce framework to facilitate big 
data processing. 
Big data processing methods can accel-
erate research in vaccines. There have been 
several proof-of-concept studies for using 
big data processing methods to improve 
efficiency in the vaccine development pro-
cess. A method for conducting phylogenetic 
analysis has been proposed. This method 
uses a cloud-based Hadoop framework (an 
implementation of the MapReduce frame-
work) to analyse evolutionary relationships 
between viruses [40]. Codon analysis is 
used in the process of vaccine development 
and an accelerated method for conducting 
this analysis using MapReduce aggregation 
has been proposed [41]. There have been 
initiatives to use big data for computational 
modelling of infectious diseases.
Vaccine efficacy trials also generate large 
volumes of data that could potentially be 
classified as big data. A vaccine efficacy trial 
for vaccination against seasonal influenza 
was conducted during the 2008-2009 season 
and involved over 43,000 participants. The 
analysis of the data collected during such 
trials could benefit from the use of big data 
methods [42].
Database
1. PUBMED
2. MEDLINE
3. Scopus
4. Web of science
5. Cochrane
Search String
“Big data”
“Big data”
“Big data” AND “health*”
“Big data” AND “health*”
“Big data”
Table 2   Search strings for literature review
1   Use Case 1: Big Data Processing
Data generation in health care systems has 
now reached exabyte levels (1 exabyte = 1 
billion gigabytes) [24, 25]. Big data technol-
ogists have a growing collection of big data 
processing techniques and we have found 
evidence that some of these techniques have 
been used within health care applications. 
We describe the more widely used big data 
processing methods.
• Distributed big data processing: Conven-
tional data processing techniques do not 
scale to meet processing requirements of 
big data. MapReduce is a distributed data 
processing method often used to process 
big data. This method adopts a two-step 
approach where the problem is first split 
into many homogenous sub-problems 
(‘map’ step) and then outputs of sub-prob-
lems are combined to generate the overall 
output (‘reduce’ step) [26]. A cloud-based 
implementation of MapReduce has been 
used to analyse electrophysiological data 
in epilepsy clinical research [27]. The in-
creased sensitivity of cardiac imaging and 
radiology equipment results in multiple 
terabytes of data being produced each 
year and frameworks such as MapReduce 
have been used for proof-of-concept 
studies in this area [28]. This process-
ing method is also commonly used in 
complex biological data processing 
operations such as genome sequencing 
which required large computation ca-
pabilities [29]. Evidence exists that big 
data processing outperforms conventional 
techniques to support the increased size 
of datasets [30]. Current statistical meth- Fig. 4   Big data processing use case diagram
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2   Use Case 2: Data Integration of Hetero-
geneous Big Data Sources 
Health care data sources used for decision 
making are no longer restricted to clini-
cal databases [43]. Accommodating this 
heterogeneity often leads to better service 
improvements and policy development. It 
is important that health care specific tech-
niques such as record linkage, and cohort 
creation, are adopted appropriately when 
using big data sources. The majority of the 
data (80%) in these sources is unstructured 
and includes medical data such as radiolog-
ical images, clinic notes, operative reports, 
and pathologic slides [44, 45]. The national 
cyber infrastructure of the United States 
has progressively improved to support the 
integration of various big data sources, 
particularly for biomedical research [46]. 
There also has been an effort to integrate 
biomedical data sources in Japan [47]. There 
is evidence of integrating big data sources in 
studies related to mental health [48]. Exam-
ples of data sources used include pervasive 
device usage data, patient workflows and 
sensor readings. The Cancer Genome Atlas 
is a publicly accessible website which acts 
as a portal to multiple big data sources and 
includes genomic data, tissue slide images 
and clinical outcomes data [49]. Evidence 
demonstrates a stream of work focusing 
on frameworks developing service-models 
based on the aggregation of data from perva-
sive computing devices (wearable body sen-
sors, body function monitors), lifestyle data 
(diet, sleep), mobility data (smartphones, 
tablets) and clinical data. Such aggregation 
helps build an understanding of the overall 
lifestyle and not only medical conditions, 
thereby leading to better preventive care.
Implications for vaccine research: This use 
case emphasises the importance of explor-
ing novel data sources that might provide a 
better understanding about the effectiveness 
of vaccines. Most accessible and growing 
data sources are available on the internet 
which has resulted in novel concepts such 
as “Infodemiology” or “Infoveillance”. 
They refer to public health data analysis by 
using the internet as the main medium which 
primarily involves aggregating information 
sources such as social media, websites and 
web blogs [50]. 
Social media has proven to be an ef-
fective source of unstructured but relevant 
information. Twitter is frequently used for 
sentiment studies as the data reflects a large 
collection of personalised contributions 
from individuals. A vaccines sentiment 
study using Twitter data was conducted and 
network clusters with strong sentiment bias 
were identified. These associations have al-
lowed the study of individuals and groups in 
the rich context of their lives, and the study 
of disease spreading at an individual person 
level [51]. Although apart from the medical 
literature, it has been shown during disas-
ters such as the Japan Earthquake or Boston 
Marathon Bombing that people are moving 
to social media like Twitter as their main 
communication tool. Social media tools 
may become better sources of contextual 
medical data than patient record systems.
Insurance claims data has been utilised as 
a useful data source for measuring vaccine 
coverage. It has been effectively used by 
systems such as PRISM (Post-licensure 
rapid immunization safety monitoring 
program) which is associated with the 
FDA’s Mini-sentinel project. This program 
currently holds data of about 107 million 
individuals collected through three health 
insurance organisations [52]. This system 
conducts an active surveillance through a 
distributed claims-based database.
Telephone triage data can also be a 
useful data source, and a proof-of-concept 
study for surveillance of Influenza-type 
diseases has been conducted [53].
Specific use case development – Effective-
ness of community flu vaccination in older 
people and Guillain Barré Syndrome as 
a possible late AE following influenza A 
vaccination: The focus of how we would 
harness these technologies for this use 
case would be to gain further insights into 
current dilemmas about effectiveness of flu 
vaccination in the community. Whilst, if the 
strain is correct, effectiveness in residential 
homes is proven, this is not known for com-
munity transmission [54-57]. A particular 
research focus would be whether children, 
and contact with children who might be 
vectors of disease, will reduce community 
cases in areas where childhood vaccination is 
piloted. A recent Cochrane review flags some 
of the limitations, and possible funding and 
publication bias of research into childhood 
vaccines to date [58]. Long term histories 
and insights into the life events of those 
with Guillain Barré Syndrome may provide 
additional insights into this condition, and 
into what might contribute to individual 
susceptibility. 
3   Use Case 3: Real-time Monitoring
Present day medical devices generate data at 
a rapid rate which is challenging especially 
when real-time responses are expected. Sim-
ilarly, when decisions need to be taken from 
aggregated data sources such as social me-
dia, data needs to be processed in real-time 
in order to benefit from the relevance of the 
insights generated from the data. Evidence in 
Fig. 5   Data integration 
of heterogeneous big data 
sources use case diagram
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our review demonstrates real-time monitoring 
as a significant use case in health care. In 
pharmacovigilance, once drugs are approved 
and available in the market, it is required to 
monitor AEs to ensure that drugs are perform-
ing as expected. AEs are generally captured by 
Adverse Event Reporting Systems and efforts 
are being made to move towards real-time 
surveillance of these events. Spontaneous 
reporting systems (SRS) are currently in use 
for drug safety monitoring [59].
We have also observed an increasing 
trend in incorporating social media as a data 
source for supporting clinical data in health 
care applications and policy development. 
The micro blogging service Twitter has so 
far been the most adopted social media 
service [60, 61]. Social media data has been 
proven to be more insightful in assessing 
patient satisfaction about the quality of care 
than conventional methods for collecting 
feedback from forms and surveys [62]. The 
HealthMap application uses social media 
data and other online web sources to per-
form infectious disease surveillance on a 
global scale [63]. Twitter and similar micro 
blogging services are increasingly used for 
public health analysis [64]. 
Implications for vaccine research: Sponta-
neous reporting systems have traditionally 
been used for monitoring vaccine safety. 
In addition, the Simplified Periodic Safety 
Update Reports (S-PSUR) and results from 
observational cohort studies are used as data 
sources for assessing vaccine safety. There 
is variability in the availability of exposure 
data in different countries and there are ini-
tiatives to develop multinational automated 
platforms for achieving this goal [65].
Surveillance of AEFI is important to detect 
potential vaccine AEs. These AEs may not 
have been identified during the prelicensure 
phase and can potentially be serious. The 
VENICE (Vaccine European New Integrated 
Collaboration Effort) project was carried out 
with the intention of harmonising the mon-
itoring of AEs across Europe [66]. With the 
advent of big data technology there is a trend 
moving from passive to active surveillance 
methods and reaching novel data sources in-
cluding data from screening during hospital-
isation, general practice networks, dispensing, 
over-the-counter sales and social media [67].
“Google flu trends” uses a novel approach 
to surveillance in which it uses internet 
search query data to predict trends in the 
spreading of infectious diseases [68]. This 
application has the advantage of being able 
to access data which cannot usually be 
integrated by public health programs due 
to various complexities [69]. This system 
identifies flu activity about two weeks earlier 
than conventional systems and is available in 
more than sixteen countries. Twitter data has 
been used to predict flu trends in a similar 
manner [70]. During the Influenza A H1N1 
pandemic, Twitter has been used to track 
levels of disease activity and public concern 
in the United States [71]. Further evidence 
in the usage of Twitter for analysing public 
health indicates the potential for vaccine 
surveillance [72]. 
 Signal detection is an important aspect 
of vaccine surveillance. A signal comprises 
information from one or more sources which 
suggests a new potentially causal association 
between an intervention and an event (either 
adverse or beneficial) [73]. Traditionally 
signals are detected using the review of 
individual and aggregated clinical reports. 
However, this process is rapidly moving to-
wards real-time signal detection through the 
development of adverse-event monitoring 
systems [74].
Systems conducting active surveillance 
will require leveraging non-clinical data 
sources to effectively detect adverse events. A 
new wave of biosecurity intelligence systems 
has effectively used web-based data sources 
for this purpose [75]. The M-Eco system has 
successfully trialled the usage of social-media 
data for signal detection [76].
Specific use case development – Febrile 
convulsions as a possible AEFI and local 
reactogenicity: We would explore the de-
velopment of a specific use case around two 
areas. Firstly, febrile convulsions as a possible 
AE following pre-school immunisation, and 
secondly around local reactivity to immunisa-
tions. There are limitations in current reporting 
systems for AEFI surveillance, they vary in 
method and by manufacturer [77]. We believe 
it would be possible to explore rates of febrile 
convulsions in children, before and after vac-
cination, and between different surveillance 
systems. We feel that local reactogenicity 
would also be amenable to this type of research 
and it maybe possible to pick up signals about 
activity and disturbed nights after immunisa-
tion. Additionally, video and picture evidence 
might also be readily collected. 
Discussion
1   Principal Findings
There is a growing evidence-base for using big 
data in health care and this has enabled gener-
alising essential use cases for big data in health 
care. By using big data approaches, our use 
cases potentially allow us to more efficiently 
achieve that goal through processing, integra-
tion and monitoring. Current data collection, 
storage, and analysis approaches are too rigid 
to support timely vaccination monitoring. This 
evidence-based approach based on use cases 
focussed on assessing vaccine benefits and 
risks. It is likely that all three areas described 
in these use cases, processing, integration, and 
real-time monitoring might have a role in future 
monitoring vaccine benefits and risks. 
Fig. 6   Real-time moni-
toring use case diagram
IMIA Yearbook of Medical Informatics 2014
33
Big Data Usage Patterns in the Health Care Domain: A Use Case Driven Approach Applied to the Assessment of Vaccination Benefits and Risks
2   Applying Use Cases to Vaccine Benefits 
and Risks Monitoring Using a Seasonal Vac-
cine and a Preventive Vaccine as Exemplars 
The benefits and risks of vaccines vary based 
on the at risk group they are administered to, 
and according to an individual disease. We use 
influenza, a seasonal and epidemic infection, 
as one example and the combined diphtheria 
tetanus and pertussis triple (DTP3) vaccine 
given as standard immunisation to children as 
another. On a worldwide basis, we still know 
relatively little about the burden of disease 
from influenza [78, 79]. By extrapolating data 
from high-income countries, the World Health 
Organisation (WHO) estimates that annual 
influenza epidemics result in around 3 to 5 
million clinically significant cases and about 
300K to 500K deaths worldwide each year. 
The WHO Global Influenza Surveillance and 
Response System (GISRS) carries out the vi-
rological analysis of around 1 million possible 
flu samples, though mainly in the developed 
world. There were about 350 million doses 
of flu vaccine administered in 2006 rising 
to around 900 million doses by 2009 [80]. 
This is a territory for big data methodologies. 
Global immunisation data provided by the 
WHO suggest that 111 million children have 
received the DTP3 vaccine in 2012 [81]. At 
this scale, this is another ideal candidate for 
exploring big data technologies.
Use case 1: Big data processing
Crowdsourcing might be a very good way to 
monitor infectious diseases if self testing or 
other validated tools could be incorporated 
into the case detection process. Crowdsourc-
ing might also provide valuable insights into 
transmission. Distributed data processing 
and predictive analysis might enhance our 
ability to predict the spread of epidemics 
and the emergence of new viral illnesses, 
and improve the search for factors associated 
with increased benefits and risks of vaccines.
Use case 2: Data integration of heteroge-
neous big data sources
Potential benefits for vaccine research may 
come from the linking of benefits and risks to 
genotype, biomarkers, and to a whole range 
of other “infomarkers.” These movement 
data may provide insight into the mechanism 
of infectious diseases spreading, about which 
we currently lack a deep understanding, 
especially from outside the developed world 
with its largely temperate climate. 
Use Case 3: Real-time monitoring
Real-time monitoring considerations might 
provide insights into any short term side-ef-
fects from seasonal immunisation, and en-
able spatial and temporal patterns of AEs to 
be described. However, real-time monitoring 
may have a greater role if it allows to high-
light emerging epidemics and disease spread 
around normal social activities – such as the 
start of the school term (which is associated 
with a rise in viral illness in the RCGP RSC), 
Christmas (where there is usually a lull), and 
from travels, or purchases of relevant over-
the-counter medications [15, 82-84].
3   Implications of Findings
The publicly available health data has the 
capability to improve the current methods of 
assessing benefits and risks of vaccines. This 
would be contingent on the demonstration 
that data applications used elsewhere in health 
care could be applied to vaccines. There 
is certainly an interest for more real-time 
applications to monitor the effectiveness of 
vaccines due the capabilities of big data pro-
cessing methods and the lower cost of utility 
computer services on the cloud. In order to 
get the maximum benefit of big data infra-
structures, vaccine-specific data processing 
methods need to be optimised. This may start 
with the real-time collection of data from 
people who are also part of current WHO 
(and/or regional) surveillance systems. This 
will be challenging to future-proof as there is 
likely to be an exponential growth of data gen-
erated from connected devices and evolving 
systems such as the Internet of Things (IoT) 
in the near future. The IoT is being explored 
as a mechanism for disaster monitoring [85]. 
Such applications may well be applicable to 
monitoring epidemics
4   Ethical Aspects of Using Big Data
As the adoption of big data increases, there 
are increased concerns about the ethical use 
of health data. Privacy and security needs 
to be considered as a primary consideration 
of any big data solution in health care, and 
the necessary legislation needs to be adopt-
ed to ensure that big data is not misused. 
Effort should be taken to keep individual 
identities from being identified during big 
data processing workflows. However, there 
is the possibility that this may result in data 
duplication during the integration of big data 
sources and affect the usefulness of big data.
Legislation in the USA such as HIPAA 
(Health Insurance Portability and Account-
ability Act) do not cover data storage outside 
of health care systems. Much of these big data 
will not be personal data and not subject to 
European legislation, and control may remain 
under the responsibility and ethics of system 
designers and owners [86]. However, this is 
a critical concern for those looking to use 
big data generated and available from online 
sources. Community driven health data re-
positories may not be as private as consumers 
assume [87]. The ownership of data generated 
through big data analytics is also constantly 
subjected to debate. Most online services 
are free and user agreements generally state 
that the owner of the service can use the data 
collected from the application. It is necessary 
to regulate data available online (especially 
health-related data). Intermediate processors 
that enforce governance restrictions may be 
an effective method to handle privacy and 
ethical concerns of big data [88].
5   Limitations of the Method
The main limitation of this method is that 
the search did not exhaustively review data 
sources that may be categorised as big data 
but not explicitly labelled as such. However, 
we feel we have identified a sufficient sample 
of big data scenarios to capture the essential 
use cases.
Conclusions
Big data is a promising advance that has the 
capability of improving care, and specifically 
help the assessment of the benefits and risks 
of vaccines beyond what can be achieved 
by just using data from a limited number 
of health care sources. There are still many 
issues related to integration and interoper-
ability of data that we have not addressed. 
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Ethical and governance issues about big data 
methods, especially in health care, are still to 
be resolved. This new paradigm of handling 
big data requires a mind shift in order to 
effectively leverage the technologies. There 
is a requirement for novel methods to be 
developed to make the most of big data. Not-
withstanding these limitations, monitoring of 
vaccines benefits and risks is one area where 
big data methods, by removing previous 
limitations on data volumes, sources, im-
mediacy, and processing power, can benefit. 
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